Darodipine (BioDeep_00000177964)

   

human metabolite blood metabolite


代谢物信息卡片


3,5-Diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid

化学式: C19H21N3O5 (371.14811360000004)
中文名称: 达罗地平
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OCC
InChI: InChI=1S/C19H21N3O5/c1-5-25-18(23)14-10(3)20-11(4)15(19(24)26-6-2)16(14)12-8-7-9-13-17(12)22-27-21-13/h7-9,16,20H,5-6H2,1-4H3

描述信息

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

3 个代谢物同义名

3,5-Diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid; 3,5-diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; Darodipine



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Sergei V Jargin. Testing of serum atherogenicity in cell cultures: questionable data published. German medical science : GMS e-journal. 2012; 10(?):Doc02. doi: 10.3205/000153. [PMID: 22355278]
  • W G Sannita, S Garbarino, D Gesino, S Massimilla, C Ogliastro. Plasma concentration and CNS effects of Ca antagonists darodipine and nimodipine after single-dose oral administration to healthy volunteers. Neuropsychobiology. 1999 Sep; 40(3):158-70. doi: 10.1159/000026614. [PMID: 10494052]
  • N Simon, E Dailly, P Jolliet, J P Tillement, S Urien. pH dependent binding of ligands to serum lipoproteins. Pharmaceutical research. 1997 Apr; 14(4):527-32. doi: 10.1023/a:1012120104615. [PMID: 9144744]
  • S Urien, Y Giroud, R S Tsai, P A Carrupt, F Brée, B Testa, J P Tillement. Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity. The Biochemical journal. 1995 Mar; 306 ( Pt 2)(?):545-9. doi: 10.1042/bj3060545. [PMID: 7887909]
  • W G Sannita, S Busico, G Di Bon, A Ferrari, S Riela. Pharmacokinetics and electroencephalographic effects of darodipine 50-200 mg modified release (MR) acute oral administration: dose-finding study in healthy volunteers. International journal of clinical pharmacology research. 1993; 13(5):281-91. doi: NULL. [PMID: 8200723]
  • J L Pinquier, S Urien, P Chaumet-Riffaud, J P Tillement. Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases. British journal of clinical pharmacology. 1989 Nov; 28(5):587-92. doi: 10.1111/j.1365-2125.1989.tb03546.x. [PMID: 2531607]
  • J L Pinquier, S Urien, M Lemaire, P Chaumet-Riffaud, J P Tillement. Comparative binding of two closely related dihydropyridines (isradipine and darodipine) to serum proteins and erythrocytes. Pharmacology. 1988; 36(5):305-12. doi: 10.1159/000138399. [PMID: 2457222]
  • S Urien, J L Pinquier, B Paquette, P Chaumet-Riffaud, J R Kiechel, J P Tillement. Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug. The Journal of pharmacology and experimental therapeutics. 1987 Jul; 242(1):349-53. doi: NULL. [PMID: 2956411]
  • R P Hof. Modification of vasopressin- and angiotensin II- induced changes by calcium antagonists in the peripheral circulation of anaesthetized rabbits. British journal of pharmacology. 1985 May; 85(1):75-87. doi: 10.1111/j.1476-5381.1985.tb08833.x. [PMID: 4027474]
  • R P Hof. PY 108-068: a calcium antagonist with an unusual pattern of cardiovascular activity. General pharmacology. 1985; 16(1):1-6. doi: 10.1016/0306-3623(85)90261-7. [PMID: 2579873]
  • R P Hof. The calcium antagonists PY 108-068 and verapamil diminish the effects of angiotensin II: sites of interaction in the peripheral circulation of anaesthetized cats. British journal of pharmacology. 1984 May; 82(1):51-60. doi: 10.1111/j.1476-5381.1984.tb16441.x. [PMID: 6733358]